Navigation Links
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
Date:5/15/2008

PRINCETON, N.J., May 15 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the second fiscal quarter ended March 31, 2008. Pharmasset reported a net loss attributable to common stockholders of $12.1 million, or ($0.57) per share for the quarter ended March 31, 2008, as compared to a net loss attributable to common stockholders of $1.7 million, or ($0.16) per share for the same period in 2007.

Revenues were $0.5 million and $5.5 million during the quarters ended March 31, 2008 and 2007, respectively. Revenues during each period reflect amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue of $0.5 million. Revenues from the year ago quarter also include a milestone payment of $5.0 million received pursuant to the Roche collaboration.

Total costs and expenses for the quarter ended March 31, 2008 were $12.8 million as compared to $7.3 million for the same period in 2007. The $5.5 million increase in total costs and expenses during the quarter ended March 31, 2008 was primarily due to a $2.9 million increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, a $1.2 million increase in compensation expense resulting from increased headcount and a $1.4 million increase in legal, insurance, audit and marketing expenses. Interest expense increased to $0.4 million during the quarter ended March 31, 2008 from $0.0 million in the quarter ended March 31, 2007. The increase was due to interest on the $10
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
2. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
3. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
4. Pharmassets Underwriters Release Shares from Lock-Up
5. Nephros Reports 2008 First Quarter Financial Results
6. PreMD Reports First Quarter Results
7. Lifeway Foods Reports Record 1st Quarter 2008 Results
8. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Cardiogenesis Reports First Quarter 2008 Results
11. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... In a study to be presented today at ... Pregnancy Meeting , in Chicago, researchers will unveil findings ... adrenal gland is a better predictor of pre-term birth ... of Maryland and Yale University have followed up on ...
... Ill. (February 4, 2010) In a study to be ... meeting, The Pregnancy Meeting , in Chicago, researchers will unveil ... for depression during pregnancy. "Depression during pregnancy is an ... the mother and the baby as well as the rest ...
... , , TORRANCE, Calif. , Feb. ... insurance brokerage and consulting firm in California , has ... best-in-class services.  An example of that commitment to quality and ... division. , TelaDoc is a national network of board-certified physicians ...
... LOUIS , Feb. 3 Young Innovations, Inc. (Nasdaq: YDNT ... 31, 2009 . , Sales for the fourth quarter of 2009 were ... from the $23.9 million reported in the fourth quarter of 2008. ... quarter of 2008 to $5.5 million in the fourth quarter of ...
... February 3, 2010 Recent immigrants to Ontario have ... term residents, according to preliminary study results from researchers at ... (ICES). "What we learned could translate into long-term health ... neurologist at St. Michael,s Hospital. "We need to do further ...
... on Wii boards, report notes , WEDNESDAY, Feb. 3 (HealthDay ... in 2006, more than just the ligaments and tendons in ... new report details foot injuries that have been incurred while ... games were introduced, patients typically presented with ligament injuries of ...
Cached Medicine News:Health News:Ultrasound measurement of fetal adrenal gland a better predictor of preterm birth 2Health News:Acupuncture found effective against depression during pregnancy 2Health News:Keenan Partners With TelaDoc for 24/7 Phone Access to Physician Network 2Health News:Keenan Partners With TelaDoc for 24/7 Phone Access to Physician Network 3Health News:Young Innovations, Inc. Announces Record EPS for the Year 2Health News:Young Innovations, Inc. Announces Record EPS for the Year 3Health News:Young Innovations, Inc. Announces Record EPS for the Year 4Health News:Young Innovations, Inc. Announces Record EPS for the Year 5Health News:Young Innovations, Inc. Announces Record EPS for the Year 6Health News:Young Innovations, Inc. Announces Record EPS for the Year 7Health News:Risk of stroke lower for recent Ontario immigrants: study 2Health News:Wii Popularity Leads to New Kind of Gaming Injury 2Health News:Wii Popularity Leads to New Kind of Gaming Injury 3
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... WATERTOWN, Mass., Oct. 17 EnVivo ... developing drugs for,neurodegenerative diseases, today announced ... Alzheimer,s, Schizophrenia and Huntington,s,diseases. EnVivo ... orally,active Alpha 7 Nicotinic Acetylcholine Receptor ...
... ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 A ... Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the French,maritime ... leads to an increase in blood flow and oxygen supply,to muscles. ...
Cached Medicine Technology:EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3
Algerbrush II corneal rust ring remover battery powered...
... the most complex grinding formula ... trial lens, are specifically manufactured ... and precision as the lenses ... RT-300 refractor. Marco custom trial ...
Khosla Mini Non-Illuminated Trial Lens Set, With Lenses Mounted...
Minus cylinders only trial lens set....
Medicine Products: